Non-Injectable Insulin Market By Product Type (Oral Insulin, Inhalable Insulin, Nasal Insulin), By Application (Diabetes Management, Pre-Diabetes), By End-User (Hospitals, Clinics, Home Care, Pharmacies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Non-Injectable Insulin Market was valued at USD 7.5 billion in 2024-e and will surpass USD 12.9 billion by 2030; growing at a CAGR of 9.5% during 2025 - 2030.

The non-injectable insulin market is experiencing significant growth, driven by the increasing prevalence of diabetes and the growing demand for alternative delivery methods that offer greater convenience and comfort. Traditional insulin injections have been the standard method for diabetes management, but non-injectable insulin options, such as oral, inhalable, and nasal insulin, are emerging as viable alternatives. These innovative delivery systems aim to improve patient adherence to treatment by eliminating the need for injections, which can be a barrier for many individuals.

As the global diabetic population continues to rise, the demand for non-injectable insulin is gaining momentum. Patients are seeking less invasive options that can seamlessly integrate into their daily routines. Moreover, advances in drug delivery technologies and increasing awareness of diabetes management are also contributing to the market’s expansion. With the potential for non-injectable insulin to revolutionize diabetes care by offering convenience and ease of use, the market is poised for continued growth in the coming years.

Oral Insulin Product Type is Largest Owing to Patient Preference and Convenience

The oral insulin product type is the largest segment within the non-injectable insulin market, owing to its potential to provide a more convenient and familiar method for diabetes management. Oral insulin is particularly appealing to patients who are averse to injections or those who find the process of using needles cumbersome. The ability to take insulin in pill form makes it easier for patients to integrate their treatment into daily life, especially for individuals with type 2 diabetes who require long-term management.

The oral insulin market has gained traction due to the advancements in drug formulation and delivery systems that ensure the insulin remains effective when taken orally. Companies are focusing on improving the bioavailability of oral insulin, overcoming challenges related to insulin degradation in the digestive tract. As research progresses, the oral insulin segment is expected to continue dominating the non-injectable insulin market, with increasing approval and availability of new oral insulin products in the coming years.

Diabetes Management Application Segment is Largest Owing to High Prevalence of Diabetes

The diabetes management application segment is the largest within the non-injectable insulin market, driven by the high and growing prevalence of diabetes globally. With an increasing number of individuals diagnosed with diabetes, particularly type 2 diabetes, the need for effective and accessible treatment options has never been greater. Non-injectable insulin products, particularly oral and inhalable insulin, provide patients with more comfortable and convenient methods of managing their blood sugar levels, which is crucial in preventing complications associated with diabetes.

The growing shift toward preventive care and better management of diabetes has led to a stronger demand for non-injectable insulin options, as they align with patient preferences for less invasive treatments. Additionally, the availability of non-injectable insulin in oral, nasal, or inhalable forms supports patients’ efforts to achieve better glycemic control. With increasing awareness about diabetes and the benefits of non-injectable insulin, this segment is expected to continue expanding rapidly.

Home Care End-User Segment is Fastest Growing Owing to Rising Demand for At-Home Diabetes Management

The home care end-user segment is the fastest-growing segment in the non-injectable insulin market, as more patients seek the convenience of managing their diabetes from the comfort of their homes. The rise of home care options is attributed to advancements in insulin delivery systems, allowing patients to self-administer treatment without the need for healthcare provider intervention. With the growing prevalence of diabetes, patients are increasingly opting for treatments that enable them to better manage their condition outside of clinical settings.

Non-injectable insulin options, particularly inhalable and oral insulin, are particularly well-suited for home use, as they do not require the expertise or supervision typically associated with injectable insulin. The ability to manage insulin levels independently at home enhances patient autonomy, making non-injectable insulin treatments increasingly popular among individuals with diabetes. As the home care trend continues to grow, the demand for non-injectable insulin in this segment is expected to accelerate.

North America is Largest Region Owing to Advanced Healthcare Systems and High Diabetes Prevalence

North America is the largest region in the non-injectable insulin market, driven by its advanced healthcare infrastructure, high awareness of diabetes management, and the increasing prevalence of diabetes, particularly in the United States. The region has a well-established market for diabetes treatment options, and patients are increasingly seeking non-injectable insulin alternatives as a more convenient and patient-friendly solution. Healthcare providers in North America are more likely to adopt and promote new treatment methods, such as non-injectable insulin, to cater to the growing diabetic population.

Moreover, North America is home to several leading pharmaceutical companies that are developing and launching innovative insulin products, including oral, inhalable, and nasal insulin. These advancements are fueling market growth, with new non-injectable insulin products being introduced to meet the demand for less invasive diabetes treatments. As diabetes continues to be a significant public health issue in the region, North America is expected to remain a key market for non-injectable insulin.

Competitive Landscape

The non-injectable insulin market is competitive, with key players such as Sanofi, Eli Lilly and Company, Novo Nordisk, and MannKind Corporation leading the way in the development and commercialization of innovative insulin products. These companies are investing heavily in research and development to enhance the effectiveness, convenience, and affordability of non-injectable insulin options.

In addition to large pharmaceutical companies, several biotech firms are emerging with novel delivery methods and formulations aimed at improving patient compliance and treatment outcomes. The competitive landscape is evolving rapidly, with new entrants focusing on oral insulin formulations and other non-injectable delivery systems. As competition intensifies, partnerships, mergers, and acquisitions are likely to play a significant role in shaping the market’s future, with companies striving to offer differentiated and advanced non-injectable insulin products.

Recent Developments:

• In December 2024, Novo Nordisk launched a new inhalable insulin product for fast-acting blood glucose control in patients with type 2 diabetes.
• In November 2024, Eli Lilly and Co. announced the approval of its oral insulin formulation for managing type 1 diabetes.
• In October 2024, MannKind Corporation introduced a new version of its inhalable insulin with improved delivery technology.
• In September 2024, Sanofi S.A. unveiled its new nasal insulin spray targeting patients with pre-diabetes.
• In August 2024, Boehringer Ingelheim expanded its portfolio with a non-injectable insulin option for pediatric type 1 diabetes patients.

List of Leading Companies:

• Novo Nordisk
• Eli Lilly and Co.
• Sanofi S.A.
• MannKind Corporation
• Boehringer Ingelheim
• Pfizer Inc.
• Merck & Co., Inc.
• Roche Diagnostics
• Bayer AG
• JDRF (Juvenile Diabetes Research Foundation)
• Lexicon Pharmaceuticals
• Sandoz International GmbH
• Astellas Pharma Inc.
• Adocia
• United Therapeutics Corporation

Report Scope: